Savara Inc - Company Profile
Powered by 
All the sales intelligence you need on Savara Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Savara Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Savara Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Savara Inc (Savara) is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Savara has undertaken several R&D initiatives, primarily focusing on the MOLBREEVI program. The R&D unit of the company is responsible for managing research and development activities, including nonclinical studies and third-party contract services for clinical trials and manufacturing development. The company has undertaken a Phase II/III randomized, double-blind, placebo-controlled trial of molgramostim in 150 patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP), known as the IMPALA trial. This was the largest controlled clinical trial in this rare disease, conducted in 18 countries, including the US, Japan, and various European countries. In FY2024, the company incurred research and development expenses of US$78 million.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer